|
NEWS CENTER
DOR
BioPharma News Releases. Click on Archives to read
prior years.
June 29, 2009
DOR BioPharma Announces Publication of orBec® Clinical Pulmonary Data in Bone Marrow Transplantation
June 09, 2009
DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec® in GI GVHD
May 15, 2009
DOR BioPharma Reports 1st Quarter 2009 Financial Results and Reviews Recent Accomplishments
March 31, 2009
DOR BioPharma Reports Year-End 2008 Financial Results and Reviews Recent Accomplishments
March 25, 2009
DOR BioPharma, Inc. Executes $400,000 Equity Investment
Agreement with Numoda Corporation
March 16, 2009
DOR BioPharma Appoints Gregg Lapointe, CPA, MBA,
to its Board of Directors
March 13, 2009
March 13, 2009
DOR BioPharma Appoints Brian L. Hamilton, MD, PhD
as Chief Medical Officer
February 12, 2009
DOR BioPharma Announces Potential $30 Million North American
Partnership Agreement with Sigma-Tau Pharmaceuticals for orBec® in
the Treatment of Graft-versus-Host Disease
January 27, 2009
DOR BioPharma Announces Appointment of Christopher J. Schaber, PhD, to BioNJ Board of Directors
January 26, 2009
DOR BioPharma Announces Formation of Acute Radiation Enteritis Medical Advisory Board
January 20, 2009
DOR BioPharma Announces Engagement of Amper, Politziner & Mattia, LLP as New Auditors
January 12, 2009
DOR BioPharma Announces Private Equity Financing of $2.28 Million with Single Institutional Investor
January 06, 2009
DOR BioPharma Obtains Fast Track Designation for DOR201 in the Prevention of Acute Radiation Enteritis
January 05, 2009
DOR BioPharma Receives SPA Clearance from the FDA to Begin Confirmatory Phase 3 Clinical Trial of orBec® in GI GVHD
December 08, 2008
DOR BioPharma Announces FDA Clearance of IND for DOR201 in Radiation Enteritis
December 01, 2008
DOR BioPharma Receives $1.5 Million from Sigma-Tau Pharmaceuticals for Exclusive Right to Negotiate orBec® Strategic Alliance
November 25, 2008
DOR BioPharma’s orBec® Receives Orphan Drug Designation in Australia for the Treatment of GI GVHD
November 14, 2008
DOR BioPharma Reports 3rd Quarter 2008 Financial Results
November 10, 2008
DOR BioPharma Receives Guidance from FDA on Proposed Confirmatory Phase 3 Clinical Trial Design of orBec® in GI GVHD
November 07, 2008
DOR BioPharma to Present at the Biotech 2008 Conference
November 05, 2008
DOR BioPharma to Present at the Rodman & Renshaw 10th Annual Investor Healthcare Conference
October 30, 2008
DOR BioPharma Announces Expansion of Named Patient Access Collaboration with BurnsAdler into Canada
September 17, 2008
DOR BioPharma Forms orBec® European Medical Advisory Board
September 15, 2008
DOR BioPharma Announces Second orBec® Clinical Summary Published in “Expert Opinion on Investigational Drugs”
September 10, 2008
DOR BioPharma Announces Named Patient Access Program for Latin America in Collaboration with BurnsAdler
August 27, 2008
DOR BioPharma Announces Named Patient Access Program for orBec® in Thailand and Other ASEAN Countries in Collaboration with Pacific Healthcare
August 15, 2008
DOR BioPharma Reports 2nd Quarter 2008 Financial Results
August 07, 2008
DOR BioPharma Announces Initiation of Second Human Clinical Trial for RiVax™, its Ricin Toxin Vaccine
July 18, 2008
DOR BioPharma Announces Named Patient Access Program for orBec® in Singapore and Malaysia in Collaboration with Steward Cross Pte Ltd
July 15, 2008
DOR BioPharma Enters into Collaborative Agreement with IDIS for Named Patient Access of orBec® in Europe
June 30, 2008
DOR BioPharma Announces Collaboration with Numoda Corporation for the Execution of Confirmatory, Phase 3 Clinical Trial of orBec®
May 23, 2008
DOR BioPharma Opens New Corporate Office in United Kingdom
May 22, 2008
DOR BioPharma Provides Update on orBec® European Regulatory and Development Strategy
May 16, 2008
DOR BioPharma Reports 1st Quarter 2008 Financial Results
May 9, 2008
DOR BioPharma Announces Appointment of
Christopher J. Schaber, PhD, to Board of Directors of the Alliance for Biosecurity
May 8, 2008
DOR BioPharma Acquires Option for
Third-Generation Anthrax Vaccine from Harvard University
April 29 , 2008
DOR BioPharma Initiates Non-Human Primate Efficacy Studies of RiVax™, its Vaccine Against Ricin Toxin
March 27 , 2008
DOR BioPharma Reports Year-End 2007 Financial Results
February 15 , 2008
DOR BioPharma Announces Named Patient Access Program for orBec® in South Korea in Collaboration with BL&H Co., Ltd.
February 14 , 2008
DOR BioPharma Enters Into $8.5 Million Common Stock Purchase Agreement
February 13 , 2008
DOR BioPharma Announces Positive New Pulmonary Effect Data from orBec® Clinical Trials
Abstract and Results to be Presented Today at Annual Tandem Bone Marrow Transplant Conference in San Diego
January 29 , 2008
DOR BioPharma Reports Achievement of Two-Year Stability Milestone for RiVaxTM
January 3 , 2008
DOR BioPharma Receives Orphan Drug Designation for Oral BDP for the Treatment of Pediatric Crohn’s Disease
|
